bioAffinity Technologies

@bioAffinity

Joined June 2020

112

Following

295

Followers

Replies Reposts Media

bioAffinity Technologies
@bioAffinity
Sep 10
Ahead of the H.C. Wainwright conference kicking off next week, $BIAF CEO Maria Zannes provides a corporate update, including CyPath® Lung’s commercial adoption, strategic milestones and advancements across the company’s technology platform. Register: bit.ly/4xn1ZRR
bioAffinity Technologies
@bioAffinity
Sep 8
An 85-year-old patient was preparing for an invasive procedure to evaluate small lung nodules revealed by low-dose CT. A negative CyPath® Lung result helped him choose follow-up imaging instead. Three months later, the nodules had resolved. cypathlung.com $BIAF
00:00
bioAffinity Technologies
@bioAffinity
Sep 4
For one patient with a history of lung cancer and advanced COPD, another biopsy carried significant risks. Dr. Gregory White shares how CyPath® Lung helped inform her care and ultimately helped her avoid another invasive procedure. $BIAF
00:00
bioAffinity Technologies
@bioAffinity
Sep 3
bioAffinity Technologies ($BIAF) President and CEO Maria Zannes will present a corporate update and hold one-on-one investor meetings at the @HCWCO 28th Annual Global Investment Conference, 9/14-9/16. Webcast: bit.ly/BIAFPresentati… | Full release: ir.bioaffinitytech.com/news-events/pr…
bioAffinity Technologies
@bioAffinity
Sep 2
Every piece of information contributes to the bigger picture when it comes to diagnosing lung cancer. CyPath® Lung complements imaging and other clinical findings by providing additional diagnostic insight to support pulmonary nodule evaluation and patient management. $BIAF
00:00